Navigation Links
GenVec to Present at the 13th Annual BIO CEO & Investor Conference
Date:2/8/2011

GAITHERSBURG, Md., Feb. 8, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq:  GNVC) today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a company overview highlighting recent developments at the 13th Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011 at 2:30 p.m. EST at the Waldorf Astoria Hotel in New York City.

A webcast of Dr. Fischer's presentation will be available both live and on replay.  To access either the live or archived webcast, log on to GenVec's website at www.genvec.com, click on "Investor Relations," and proceed to "Webcasts & Data."  The replay will be available 3 hours after the live presentation and will be accessible for 30 days.

About GenVecGenVec, Inc. is a biopharmaceutical company using superior, proprietary technology to create differentiated vaccines and therapeutics that are developed and commercialized through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the US Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), HSV-2, dengue fever, influenza, HIV, malaria, and foot-and-mouth disease. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.Investor and Media Contact: GenVec, Inc. Douglas J. Swirsky (240) 632-5510 dswirsky@genvec.com
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
2. GenVec Reports Third Quarter 2009 Financial Results
3. GenVec Announces Third Quarter 2009 Results Conference Call
4. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
5. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
6. GenVec Reports Second Quarter 2009 Financial Results
7. GenVec Expands Contract Supporting Malaria Vaccine Program
8. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
9. Lexicon Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference
10. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
11. Mosaic to Present at Goldman Sachs Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., ... Advisory Board. Dr. Lamka will assist PathSensors in expanding the use of the ... deploys the CANARY® test platform for the detection of harmful pathogens, including a ...
(Date:4/27/2016)... April 27, 2016 MedDay, a biotechnology ... announces the appointment of Catherine Moukheibir as Chairman of its ... Chairman, Jean Jacques Garaud , who contributed to the ... effective immediately. Catherine started her career in strategy ... and London .  She held C-Suite level ...
(Date:4/26/2016)... CAMBRIDGE, Mass. (PRWEB) , ... April 26, 2016 , ... ... Herr has been selected as one of three finalists for the European Inventor ... the EPO’s annual innovation prize will be announced at a ceremony in Lisbon on ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a ... round of financing. Healthy investor interest drove significant oversubscription of the original $1.5M ... known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):